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Hyperferritinemia has been associated with adverse outcomes after allogeneic hematopoietic cell trans-
plantation (allo-HCT) with myeloablative conditioning. However, its characteristics and impact on the
outcome in the reduced-intensity conditioning (RIC) and in the lymphoid malignancy settings are far from
clear. The study includes 201 adult patients undergoing allo-HCT with RIC (allo-RIC) for lymphoid malig-
nancies with a median follow-up for survivors of 52 months (range, 3 to 123). Median serum ferritin level at
allo-RIC was 379 ng/mL (range, 4 to 10,790). In the multivariate analysis, patients with hyperferritinemia at
transplantation (>399 ng/mL) showed lower 4-year overall survival (hazard ratio [HR], 1.8 [95% conﬁdence
interval {CI}, 1.2 to 2.8]; P ¼ .008), higher nonrelapse mortality (NRM) (HR, 1.8 [95% CI, 1.1 to 3.2]; P ¼ .03), and
higher infection-related mortality (HR, 2.3 [95% CI, 1.1 to 4.8]; P ¼ .02) than patients without hyper-
ferritinemia. Neutrophil and platelet engraftment and 100-day NRM were similar between both groups. The
adverse outcome associated with hyperferritinemia seemed higher in patients without major comorbidities
and was not inﬂuenced by the elevation of acute phase reactants. Our results indicate that high ferritin levels
at HCT are associated with an adverse outcome after allo-RIC in patients with lymphoid malignancies.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION allo-RIC recipients with lymphoid malignancies with a long
The negative effect of hyperferritinemia on the outcome of
allogeneic hematopoietic cell transplantation (allo-HCT) has
been increasingly identiﬁed during the last years. Serum
ferritin has been widely used as a surrogate marker of iron
overload, and elevated levels have been associated with an
adverse outcome of the procedure [1-4]. Nevertheless, the
impact of hyperferritinemia on nonrelapse mortality (NRM)
seems clearer in the myeloablative conditioning setting
than in the reduced-intensity conditioning (RIC) setting,
where the few studies available show contradictory results
regarding its effect on NRM in these patients [5-7]. Hyper-
ferritinemia has been demonstrated in patients with
lymphoma and myeloma, and its negative impact has been
suggested in the autologousHCTsetting [8]. Nevertheless, the
inﬂuence of hyperferritinemia has only been evaluated in
myeloid malignancies or in heterogeneous populations of
allo-HCT recipients but not to our knowledge, exclusively in
patients with lymphoid malignancies. In an attempt to reach
a better understanding of the impact of hyperferritinemia
before allo-HCT on the outcome of the procedure, we
conducted a study in a highly homogeneous population ofdgments on page 601.
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METHODS
Patients
The study included all consecutive adult patients with lymphoprolifer-
ative disorders who received an allo-RIC in three transplantation centers in
Spain (Hospital de la Santa Creu i Sant Pau, Barcelona; Hospital Clínic, Bar-
celona; and Hospital Universitario, Salamanca) between February 1998 and
November 2008. Lymphoproliferative disorders included were high-grade
non-Hodgkin lymphoma, low-grade non-Hodgkin lymphoma, Hodgkin
lymphoma, chronic lymphocytic leukemia, and multiple myeloma. Of the
258 patients who underwent transplantation during the study period, 201
(78%) had available information on ferritin, transferrin saturation, acute-
phase reactants, and albumin levels at HCT and were included in the
study. The transplantation protocols were approved by national ethics
committees, and patients gave written informed consent for their inclusion
in each protocol.
Conditioning Regimen, Graft-versus-Host Disease Prophylaxis, and
Supportive Care
All patients were treated with the same protocol, published elsewhere
[9]. RIC instead of myeloablative conditioning was preferred in patients with
at least one of the following: age >50 years, previous autologous HCT, or
severe comorbidities. The conditioning regimen for all patients included
ﬂudarabine (150mg/m2) in combinationwithmelphalan (70 to 140mg/m2).
Graft-versus-host disease (GVHD) prophylaxis included cyclosporine A plus
short-course methotrexate (daysþ1,þ3,þ6, andþ11 at 10 mg/m2, followed
by folinic acid rescue) or cyclosporine A plus mycophenolate mofetil 1 g
twice daily or cyclosporine A with or without steroids in a few patients
receiving antithymocyte globulin. T cell depletion was used in patients
receiving a transplantation from human leukocyte antigen (HLA) mis-
matched donors.
Acyclovir, ﬂuconazole, and quinolones (ciproﬂoxacin or norﬂoxacin)
were administered as infectious prophylaxis. Cytomegalovirus infection
screening (using antigenemia pp65 before 2003 and RT-PCR after 2003) forTransplantation.
Table 1
Patients Characteristics
Characteristics All Patients (n ¼ 201) Ferritin >399 ng/mL (n ¼ 94) Ferritin 399 ng/mL (n ¼ 107) P Value
Median age, y (range) 51 (19-67) 50 (20-67) 51 (19-65) .6
Gender male, n (%) 120 (60) 65 (69) 55 (51) .07
Female donor to male recipient 54 (27) 27 (29) 27 (25) .6
Underlying disease, n (%)
Hodgkin lymphoma 45 (22) 25 (27) 20 (19) .2
NHL 68 (34) 35 (37) 33 (31) d
CLL 33 (16) 18 (19) 15 (14) d
Multiple myeloma 55 (27) 16 (17) 39 (36) d
Disease status
CR 59 (29) 23 (24) 36 (34) .1
PR 105 (52) 47 (50) 58 (54) d
NR/progressive 37 (18) 24 (25) 13 (12) d
Advanced disease* 166 (83) 81 (86) 86 (80) .3
Previous SCT 102 (51) 49 (52) 53 (50) .5
Time from diagnosis to HCT (>12months) 174 (87) 87 (89) 87 (81) .2
Recipient/donor CMV serology, n (%)
Recipient and donor negative 21 (10) 10 (9) 11 (10) .8
Recipient and/or donor positive 180 (90) 84 (89) 96 (90) -
Donor type, n (%)
HLA identical sibling 164 (82) 74 (79) 90 (84) 1.0
Alternative (VUD or MM related) 37 (18) 21 (21) 16 (16) d
T cell depletion,y n (%) 30 (15) 15 (16) 15 (15) .7
Peripheral blood stem cells, n (%) 191 (95) 87 (93) 104 (97) .7
GVHD prophylaxis, n (%)
CsA-MTX 143 (71) 67 (71) 76 (71) 1.0
CsA-MMF 47 (23) 20 (21) 27 (25) .6
Other 11 (5) 7 (7) 4 (4) .7
NHL indicates non-Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; CsA, cyclosporine A; MTX, methotrexate; MMF, mycophenolate mofetil; CMV,
cytomegalovirus; VUD, volunteer unrelated donor; MM, HLA mismatch; CR, complete remission; PR, partial remission; NR, nonresponse.
* Advanced disease was considered following the European Group for Blood and Marrow Transplantation criteria [14].
y T cell depletion includes patients receiving antithymocyte globulin (n ¼ 22) or alemtuzumab (n ¼ 8) as part of the conditioning.
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detail [10]. Galactomannan Platelia assay (Bio-Rad Laboratories, Hercules,
CA) in blood samples was routinely performed since 2003 [11]. Patients
included in the study did not receive phlebotomies or chelation therapy
before transplantation.
Iron Parameters Determination and Laboratory Analysis
All laboratory tests performedwithin the 30 days before transplantation
were included in the analysis. Ferritin, transferrin saturation, and albumin
determinations were performed using standard procedures in each center’s
laboratory. Erythrocyte sedimentation rate (ESR) and C-reactive protein
(CRP) were the acute-phase reactants considered for the analysis. High ESR
and CRP were considered above 10 mm/h for men and 15 mm/h for women
and 10 mg/L, respectively. When both markers were available, CRP was
preferred because it appears to be a more accurate inﬂammation marker
than ESR [12]. Hepatic or cardiacmagnetic resonance imaging or liver biopsy
to determine iron liver content were not routinely performed in any of the
centers in allo-HCT recipients.
Study Deﬁnitions, Endpoints, and Statistical Analysis
Hyperferritinemia was deﬁned as ferritin levels above the value with
higher sensitivity and speciﬁcity for overall survival (OS) determined by the
analysis of the receiver-operating characteristic curves. NRMwas deﬁned as
the time from day 0 of the transplantation to death from any cause but
relapse. Infection-related mortality (IRM) was deﬁned as patients whose
main cause of death was considered to be a clinical and/or microbiological
documented infection. To exclude the inﬂuence of inﬂammation in a single
ferritin determination, we also included CRP/ESR and albumin determina-
tions in the same time point as positive and negative inﬂammation markers,
respectively.
Patients were classiﬁed into four risk groups for 4-year NRM according
to the ferritin and CRP/ESR levels: group 1, ferritin399 ng/mL and low CRP/
ESR; group 2, ferritin 399 ng/mL and high CRP/ESR; group 3, ferritin >399
ng/mL and low CRP/ESR; and group 4, ferritin >399 ng/mL and high CRP/
ESR. The HCT comorbidity index was calculated as originally deﬁned [13],
and advanced risk was deﬁned following the European Group for Blood and
Marrow Transplantation criteria [14].
The primary endpoint of the study was to determine the impact of high
ferritin levels before transplantation on OS and NRM after allo-RIC. The
secondary endpoint was to describe the characteristics of patients with high
ferritin levels at HCT.The probability of OS was estimated from the time of transplantation
using Kaplan-Meier curves [15] and compared using log-rank tests. Cumu-
lative incidence of NRM and IRM was estimated by using competitive risk
method with the Gray test. Comparison of characteristics between patients
with high and low ferritin levels was performed using 2  2 tables made by
means of chi-square or Fisher exact t-tests for dichotomic variables and by
means of t-test for continuous variables. Univariate Cox regression analysis
was used to estimate risk factors of NRM, OS, and relapse. Variables tested in
theunivariateCox regression analysis for transplantationoutcomes appear in
Table 2. Multivariate analysis was performed taking into account the
competing risk structure [16,17], including those variableswith a signiﬁcance
level of P  .1 in the univariate Cox regression analysis.
All statistical analyses were performed using SPSS version 17.0 (SPSS,
Chicago, IL). The exception was the cumulative incidence analyses, which
were carried out with NCSS 2004 (Number Cruncher Statistical System,
Kaysville, UT).
RESULTS
Patient Characteristics
Pretransplantation characteristics and outcome (4-year
NRM and 4-year OS) were similar between the 201
patients included in the study and the 57 patients in the
cohort not included due to missing data on iron parameters
(Supplementary Table 1). Pretransplantation characteristics
of the patients in the study are summarized in Table 1. One
hundred two patients had received a previous autologous
HCT. Among patients 50 years (n ¼ 101), RIC was chosen
because of pervious autologous HCT (n ¼ 73) and severe
comorbidities (n ¼ 28). Median follow-up for survivors was
52 months (range, 3 to 123).
Ferritin Levels at HCT
The median ferritin level at transplantation was 379 ng/
mL (range, 4 to 10,790). Quartile distribution of ferritin levels
was as follows: quartile 1, 4 to 129; quartile 2, 130 to 379;
quartile 3, 380 to 851; and quartile 4, 852 to 10,790. Forty-
four patients (22%) had ferritin levels >1,000 ng/mL at
Figure 1. Impact of high ferritin levels on OS, NRM, and relapse. Probability of OS and cumulative incidence of NRM and relapse in patients with high ferritin levels
(>399 ng/mL) (dashed lines) and low ferritin levels (399 ng/mL) (continuous line). Multivariate analysis.
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considered for values >399 ng/mL according to the receiver-
operating characteristic curve results.
Outcome
Neutrophil and platelet engraftment
Median time for neutrophil (>.5  109/L) and platelet
(>50  109/L) engraftment was 15 days (range, 9 to 202)
and 15 days (range, 7 to 203), respectively. Patients with and
without high ferritin levels at HCT showed similar median
time to neutrophil (15 vs 14 days, P ¼ .3) and platelet (14 vs
15 days, P¼ .3) recovery. Risk factors for a delayed neutrophil
engraftment were age >60 years (median, 18 vs 14 days,
P ¼ .04) and bone marrow as stem cell source (median, 24 vs
15 days, P< .001). The only factor that had an adverse impact
on platelet engraftment was non-HLA identical sibling
donors (median, 19 vs 14 days; P ¼ .006).
NRM, IRM, OS and relapse
Twenty-seven (13%) and 77 patients (38%) died fromNRM
at 100 days and at median follow-up, respectively (Figure 1).Table 2
Univariate and Multivariate Analysis of Pretransplant Variables on Transplantation
Variables NRM P Value
Univariate analysis
Ferritin >399 mg/dL 2.1 (1.2-3.6) .005
High acute-phase react. 0.9 (0.5-1.5) .6
Transferrin sat. >65% 1 (0.4-2.2) 1
CMV status neg-neg 0.6 (0.3-1.6) .3
High risk 0.9 (0.5-1.7) .9
PBSC vs other 1.2 (0.3-4.7) .8
MM vs lymphoma 0.4 (0.2-0.8) .01
Time to HCT >12 mo 1 (0.4-2.5) 1.0
CsA-MMF* 2.3 (1.3-3.7) .002
TCD 1.5 (0.8-2.7) .2
Alb  40 0.7 (0.4-1.1) .15
Age > 60 2.4 (1.4-4.1) .002
HLA alternative 1.8 (1-3.2) .04
Female to male 1.6 (1-2.7) .06
EBMT score > 4* 2.7 (1.6-4.6) <.001
HCT-CI > 2 1.8 (1.2-2.7) .006
Multivariate analysis
Ferritin >399 ng/mL 1.8 (1.1-3.2) .03
Age > 60 3.2 (1.8-5.8) <.001
HLA alternative 2.1 (1.2-4.3) .02
Female to male 1.9 (1.1-3.3) .02
MM vs lymphoma 0.5 (0.2-1) .06
HCT-CI > 2 1.9 (1.1-3.4) .02
CMV indicates cytomegalovirus; PBSC, peripheral blood stem cell; MM, multiple my
comorbidity index; EBMT, disease; sat., saturation; react., reactants; TCD, T cell de
High acute phase reactants are deﬁned as erythrocyte sedimentation rate >10 m
Methods).
* All variables in the univariate analysis were included in the multivariate analyCumulative incidence of 100-day and 4-year NRM was 11%
(95% conﬁdence interval [CI], 9 to 13) and 31% (95% CI, 27 to
34), respectively. Main causes of NRM included GVHD and
infections (28 patients died from GVHD with infection, 26
from infection without GVHD, and 17 from GVHD without
infection). IRM occurred in 35 patients (18%) for a cumulative
incidence at 4 years of 15% (95% CI, 13 to 19). Nineteen
patients dying from GVHD and infection presented with an
infection that was considered a contributive but not themain
cause of death. Patients with and without high ferritin levels
showed similar risk of 100-day NRM (hazard ratio [HR], 1.6
[95% CI, .8 to 2.9]; P¼ .2), although patients with high ferritin
levels at HCT showed higher 4-year NRM (HR, 1.8 [95% CI, 1.2
to 1.8]; P¼ .008) and higher 4-year IRM (HR, 2.3 [95% CI,1.1 to
4.8]; P ¼ .02) in the multivariate analysis (Figure 1). Other
risk factors for 4-year NRM were age (>60 years), non-HLA
identical sibling donors, sex mismatch (female donors to
male recipients), and HCT comorbidity index 3 (Table 2).
In the subgroup analysis, the impact of high ferritin levels
on NRM was greater in patients with low HCT comorbidity
index score (0 to 2) than in the higher HCTcomorbidity indexOutcomes
OS P Value IRM P Value
1.9 (1.2-2.8) .004 2.2 (1.1-4.4) .03
1 (0.6-1.5) 1.0 0.9 (0.4-1.8) .8
1.3 (0.7-2.5) .4 1.4 (0.6-3.4) .5
0.6 (0.3-1.2) .2 0.9 (0.3-2.5) .8
1.2 (0.7-2.1) .5 1 (0.4-2) .8
1 (0.5-2.4) .9 0.6 (0.1-3.3) .6
0.7 (0.5-1.2) .2 0.5 (0.2-1.2) .13
1.2 (0.6-2.4) .6 0.7 (0.2-2.7) .6
1.6 (1.1-2.6) .02 2.5 (1.3-4.8) .006
1.3 (0.7-2.1) .4 1.6 (0.7-3.5) .2
0.7 (0.5-1.1) .12 0.8 (0.4-1.5) .5
1.9 (1.2-3) .01 2.5 (1.2-5) .01
1.4 (0.9-2.3) .18 1.5 (0.7-3.3) .3
1.5 (1-2.2) .07 2.7 (1.4-5.2) .002
1.8 (1.2-2.9) .007 3.7 (1.9-7.4) <.001
2.1 (1.2-3.6) .006 1.5 (0.8-3) .2
1.8 (1.2-2.8) .008 2.3 (1.1-4.8) .02
2.1 (1.3-3.4) .003 2.3 (1.1-4.8) .03
- - - -
1.5 (0.9-2.3) .09 3 (1.5-5.9) .002
- - - -
1.6 (1.1-2.5) .03 - -
eloma; MMF, mycophenolate mofetil; CsA, cyclosporine A; Alb, albumin; CI,
pletion.
m/h for men or 15 mm/h for women or C-reactive protein >10 mg/L (see
sis except for those that showed colinearity with other variables.
Figure 2. NRM according to ferritin levels and acute-phase reactants at allo-
HCT. Cumulative incidence of NRM according to the combination of ferritin
and CRP/ESR levels. Patients with high ferritin levels (>399 ng/mL) with either
high or low levels of acute-phase reactants (HR, 4.1 [95% CI, 0.9 to 17.1]; P ¼ .06
and HR 3.9 [95% CI, .8 to 19.2]; P ¼ .1, respectively) had a trend to a higher risk
of NRM than patients with low ferritin levels with high or low acute phase
reactants (HR, 1.5 [95% CI, .3 to 7.2]; P ¼ .6 and HR 1.0 [reference], respectively).
The impact of high levels of CRP/ESR alone on transplantation outcomes is
summarized in Table 2.
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[95% CI, .8 to 3]; P¼ .2, respectively). The risks of 4-year NRM
according to ferritin and CRP/ESR levels were as follows:
group 1 (ferritin 399 ng/mL and low CRP/ESR), HR 1.0;
group 2 (ferritin 399 ng/mL and high CRP/ESR), HR 1.5 (95%
CI, .3 to 7.2), P ¼ .6; group 3 (ferritin >399 ng/mL and low
CRP/ESR), HR 3.9 (95% CI, .8 to 19.2), P ¼ .1; and group 4
(ferritin >399 ng/mL and high CRP/ESR), HR 4.1 (95% CI, .9 to
17.1), P ¼ .06 (Figure 2).
A total of 106 (53%) patients remained alive at median
follow-up, for a probability of 4-year OS of 50% (95% CI, 45 to
55). In the multivariate analysis, patients with high ferritin
levels had lower 4-year OS than patients without (HR, 1.8
[95% CI, 1.2 to 2.8]; P ¼ .008). Other risk factors for lower OS
were age>60 years and HCT comorbidity index 3 (Table 2).
Globally, 65 patients (32%) experienced relapse of base-
line disease for a cumulative incidence at 4 years of 33% (95%
CI, 29 to 37) at a median time of 234 days (range, 52 to 1,807)
after allo-RIC. Patients with and without high ferritin levels
at HCT showed similar risk of relapse (HR, 1.1 [95% CI, .7 to
1.8]; P ¼ .7).
DISCUSSION
Our study,which is the largest toaddress the issueof ferritin
levels in patients undergoing allo-RIC, demonstrates a consis-
tent prognostic effect of pretransplantation hyperferritinemia
seenby lowerOSthroughaneffectonNRMand IRM inpatients
with lymphoidmalignancies. Thedeleterious effect on survival
seemed greater in patients with low comorbidities.
The effect of high ferritin levels on the outcome of HCT
seems to have some particularities according to the intensity
of the conditioning regimen. In the myeloablative setting, its
impact on NRM has been demonstrated and widely repro-
duced in most [1-4], although not all [18], studies. The
increased risk of NRMwas translated into a lower OS in most
studies. On the other hand, in the few studies focused on the
RIC setting, the interpretation of the results seems to bemore
challenging. Some authors suggested amitigated effect of the
RIC on the generation of free radicals and other toxic mech-
anisms comparedwithmore aggressive therapies included in
the myeloablative conditionings, like high-dose alkylatingagents and total-body irradiation. Because this generation of
hydroxyl free radicals by nontransferrin bound iron is key for
the organ damage, its lower production in patients receiving
RICwould lead to attenuated end-organ toxicity [4].Whereas
in the majority of the RIC studies, higher ferritin levels were
associated with lower OS, the risk of NRM and relapse [5,6]
was not affected, making it difﬁcult to explain such a differ-
ence in OS. Ours is the ﬁrst large study to demonstrate
a prognostic signiﬁcance of pretransplantation ferritin levels
on NRM in the RIC setting. The homogeneity of our patients
and the statistical power of our relatively large cohort might
explain our results in contrast of others’ results. To strengthen
the consistency of our analysis, we conﬁrmed this impact
using two different cutoff points for high ferritin levels: the
level obtained by the receiver-operating characteristic curve
analysis (399 ng/mL) and a more arbitrary although clinically
used level (1,000 ng/mL) (Supplementary Table 2).
Moreover, the impact on NRM was more profound in
patients with less severe comorbidities (HCT comorbidity
index <3). A possible explanation for this ﬁnding is that
patients with an HCT comorbidity index 3 already have
a high probability of NRM (35% to 40% at 2 years) [13,19]. In
this high-risk population, the deleterious effect of hyper-
ferritinemia would make little difference. On the other hand,
in patients with an expected lower risk of NRM, as in patients
without a low HCT comorbidity index score, the addition of
a risk factor (such as hyperferritinemia) would increase the
risk of NRM. The potential interest of combining ferritin
levels and comorbidities in pretransplantation predictive
models has been suggested [20] but, to our knowledge, has
not been carried out. Future models should take our ﬁndings
into account because ferritin levels might not have the same
impact in patients with or without comorbidities.
Patients with lymphoid malignancies seem to have lower
ferritin levels than patients with myeloid neoplasms at HCT
[4]. Despite difﬁculties in comparing studies, we also showed
a lower median ferritin level than that reported in other RIC
studies including patients with myeloid diseases [5,21]. In
addition, our results show that the deleterious effect of
hyperferritinemia suggested in the myeloid setting is also
observed in lymphoid malignancies.
One limitation of our study is the use of ferritin as
a surrogate marker of iron overload, as it is an acute-phase
reactant. Some concerns have been raised around the fact
that ferritin levels might be altered by infections, baseline
disease status, and, in general, by any cause of inﬂammation,
and they may not truly reﬂect the iron overload in a partic-
ular patient. To partially mitigate this effect, we included
positive and negative inﬂammation markers (CRP/ESR and
albumin, respectively) in the analysis and showed that
despite lower numbers of patients, a trend to a deleterious
effect of high ferritin levels persisted independently of the
elevation of acute-phase reactants (Figure 2). Acknowledging
the limitations of ESR as a less sensitive marker than CRP, we
considered it valuable to include this variable in the analysis
for patients without available CRP levels to lower the
inﬂammatory effect on high ferritin levels. Despite these
concerns, ferritin levels are probably the most cost-effective
and easily available measure to determine iron overload in
most centers. Thus, in line with other authors [2,5], we
consider that ferritin is a potentially valid tool for iron
overload measure in the allo-HCT setting.
Ours and others’ results raise the question of reduction of
hyperferritinemia in the allo-HCT setting. There are several
windows for intervention. The ﬁrst one is trying to reduce
P. Barba et al. / Biol Blood Marrow Transplant 19 (2013) 597e601 601ferritin levels before allo-HCT [22], although a short time
from diagnosis to transplantation or drug interactions might
limit its use. On the other hand, post-transplantation ferritin-
reduction strategies (either with phlebotomies or chelation
drugs) beginning a few months after HCT seem to be safe
[23,24] and might improve disease-free survival in patients
with hematological malignancies [25]. Finally, preliminary
studies [26] have suggested that the use of deferasirox
during the conditioning regimen is safe and may prevent
the appearance of labile plasma iron (a fraction of
nontransferrin-bound iron) shortly after HCT, although
deﬁnitive publication of these results is awaited.
In conclusion, our study, conducted in a large and
homogeneous population, supports that high ferritin levels
occur in patients with lymphoid malignancies. Furthermore,
they are associated with worse outcome after allo-RIC.
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